ALK and non-small cell lung carcinoma: The promising result of the PROFILE 1007 trial led to the phase III PROFILE 1014 clinical study, with the goal to assess the efficacy of the ALK inhibitor crizotinib compared with standard chemotherapy with pemetrexed plus platinum as the first-line treatment for metastatic ALK-positive NSCLC patients.